Search Results

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today reported financial information for the first quarter of 2024, including its cash, cash equivalents and revenues, and provided a corporate update.

Inventiva announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver on June 5-8, 2024 in Milan, Italy.

Inventiva announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.

Inventiva announced the positive recommendation from the fourth scheduled meeting of the Data Monitoring Committee to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with MASH/NASH without modification to the current trial protocol.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its full-year results for 2023.